Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a report issued on Friday.

Several other research firms have also recently weighed in on MCRB. Canaccord Genuity Group reissued a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a research report on Thursday, November 14th. Chardan Capital reissued a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. cut shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Seres Therapeutics currently has an average rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Price Performance

Shares of NASDAQ:MCRB opened at $0.91 on Friday. The business’s 50 day moving average price is $0.82 and its 200-day moving average price is $0.90. The firm has a market capitalization of $154.59 million, a PE ratio of -3.94 and a beta of 2.07. Seres Therapeutics has a 1 year low of $0.54 and a 1 year high of $2.05.

Hedge Funds Weigh In On Seres Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Providence Wealth Advisors LLC increased its holdings in shares of Seres Therapeutics by 49.5% in the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 25,250 shares during the last quarter. Point72 DIFC Ltd acquired a new position in Seres Therapeutics in the second quarter valued at approximately $64,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Seres Therapeutics in the second quarter valued at approximately $92,000. Vontobel Holding Ltd. acquired a new stake in Seres Therapeutics during the third quarter worth approximately $374,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Seres Therapeutics by 42.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after purchasing an additional 222,771 shares in the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.